Cipla Ltd
As of 20 Nov 2026, Cipla is in Stage 3, the topping phase, now in week 9 (since 17 Sep 2026). It closed at ₹1,415, 7.9% below its 52-week high and above its 200-day average, which is falling. In Health Care, 34.7% of stocks are in Stage 2.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. More about the company
Pro read
ProCIPLA's uptrend is tiring: about 2 months into a top. A topping stock either breaks back out or rolls over into a decline, and the next few weeks usually settle which.
Its relative strength is 57 of 99, above the middle among NSE stocks over the past year. Pharmaceuticals ranks 7 of 106 industries by the strength of its stocks, among the leaders.
Is CIPLA early, or has it already run? Pro answers that for every NSE stock, after every close.
CIPLA among Pharmaceuticals76th of 118 by relative strength
All 118 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | BLISSGVS | Stage 2 · wk 49 | 99 | +4.6% |
| 2 | KPL | Stage 2 · wk 44 | 99 | +20.5% |
| 3 | FREDUN | Stage 2 · wk 33 | 98 | +24.0% |
| 4 | VENUSREM | Stage 3 · wk 10 | 98 | −1.5% |
| 5 | RUBICON | Stage 3 · wk 4 | 98 | +18.7% |
| 6 | SAKAR | Stage 2 · wk 55 | 98 | +13.1% |
| 7 | BAFNAPH | Stage 2 · wk 23 | 98 | +1.9% |
| 8 | INDSWFTLAB | Stage 2 · wk 23 | 98 | −7.4% |
| …76 | CIPLA | Stage 3 · wk 9 | 57 | +7.7% |
Mutual fund holdings
Held by 189 mutual funds in portfolios to October 2026: 100 active funds and 89 index funds and ETFs.
In October, among active funds: 22 increased, 3 opened a new position, 11 reduced and 4 exited.
All 189 funds, the 4 that exited, and what each did in October
Mutual funds holding CIPLA: the ten largest and the month’s moves →
Cipla: quick answers
What stage is Cipla in?
As of 20 Nov 2026, Cipla (CIPLA) is in Stage 3, the topping phase. It entered Stage 3 on 17 Sep 2026 and is in week 9. What the four stages mean
Is Cipla in an uptrend?
Its uptrend has stalled. Cipla is in Stage 3, the topping phase that follows an advance. It trades 3.6% above its 200-day average, which is falling.
How far is Cipla from its 52-week high?
Cipla closed at ₹1,415 on 20 Nov 2026, 7.9% below its 52-week high of ₹1,536. Its 52-week low is ₹1,192.
How has Cipla performed over the past year?
As of 20 Nov 2026, Cipla is down 7.3% over the past year and down 6.4% so far in 2026.
Is Cipla in F&O, and what is its lot size?
Yes. Cipla (CIPLA) trades in NSE's F&O segment, with a near-month lot size of 425 shares as of 20 Nov 2026. NSE revises lot sizes a few times a year; ours are reloaded from the exchange's list after every close.
Which sector and industry is Cipla in?
Cipla is in the Pharmaceuticals industry, part of the Health Care sector. 61 stocks in Health Care are in Stage 2, 34.7% of the sector. See the Stage 2 stocks in Pharmaceuticals
About this companyHealth Care· Pharmaceuticals
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Visit company website →All analytics based on EOD data. Data as of 2026-11-20. Past data patterns are not indicative of future results. This page is a data analytics tool only.